Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate

Clinical Infectious Diseases

Volumn 58, Issue SUPPL. 1, 2014, Pages

  Lodise, Thomas P ^a   Drusano, G L ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEDIZOLID;

AREA UNDER THE CURVE; ARTICLE; DRUG DISPOSITION; EPITHELIUM; GRANULOCYTE; HUMAN; LUNG; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS NEUTROPENIC PNEUMONIA; STAPHYLOCOCCUS INFECTION; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; HUMANS; MICROBIAL SENSITIVITY TESTS; ORGANOPHOSPHATES; OXAZOLES; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84892183660     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit615     Document Type: Article

References (44)

1. French GL. The continuing crisis in antibiotic resistance. Int J Antimicrob Agents 2010; 36 (Suppl 3):S3-7
2. Gottlieb T, Nimmo GR. Antibiotic resistance is an emerging threat to public health: An urgent call to action at the Antimicrobial Resistance Summit 2011. Med J Aust 2011; 194:281-3
3. Theuretzbacher U. Accelerating resistance, inadequate antibacterial drug pipelines and international responses. Int J Antimicrob Agents 2012; 39:295-9
4. Institute of Medicine (US) Forum on Microbial Threats. Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies: Workshop Summary. Washington, DC: National Academies Press, 2010
5. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE surveillance program (2008-2010). Clin Infect Dis 2012; 55 (Suppl 3):S206-14
6. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51 (Suppl 1):S81-7
7. Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: Report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 2013; 75:107-9
8. Sader HS, Farrell DJ, Jones RN. Antimicrobial susceptibility of Grampositive cocci isolated from skin and skin-structure infections in European medical centres. Int J Antimicrob Agents 2010; 36:28-32
9. Sader HS, Moet GJ, Farrell DJ, Jones RN. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillinresistant Staphylococcus aureus and vancomycin-resistant enterococci: Trend analysis of a 6-year period in US medical centers (2005-2010).Diagn Microbiol Infect Dis 2011; 70:412-6
10. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71
11. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis 2011; 52:285-92
12. de Almeida LM, Lincopan N, de Araújo MR, Mamizuka EM. Clonal dissemination of linezolid-resistant Staphylococcus haemolyticus exhibiting the G2576 T mutation in the 23S rRNA gene in a tertiary care hospital in Brazil. Antimicrob Agents Chemother 2012; 56:2792-3
13. Passalacqua KD, Satola SW, Crispell EK, Read TD. A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin. Antimicrob Agents Chemother 2012; 56:5212-23
14. Picazo JJ, Betriu C, Rodriguez-Avial I, Culebras E, Lopez-Fabal F, Gomez M. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance. Diagn Microbiol Infect Dis 2011; 70:373-9
15. Quiles-Melero I, Garcia-Perea A, de Pablos M, Gomez-Gil R, Mingorance J. Resistance to linezolid in a methicillin-susceptible Staphylococcus aureus clinical isolate without previous exposure to oxazolidinones. Int J Med Microbiol 2012; 302:145-7
16. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: Look before you leap!. Clin Infect Dis 2010; 51 (Suppl 1):S103-10
17. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin Infect Dis 2007; 44:79-86
18. Miller R, Ewy W, Corrigan BW, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005; 32:185-97
19. Schmidt S, Barbour A, Sahre M, Rand KH, Derendorf H. PK/PD: New insights for antibacterial and antiviral applications. Curr Opin Pharmacol 2008; 8:549-56
20. Drusano GL. Antimicrobial pharmacodynamics: Critical interactions of"bug and drug." Nat Rev Microbiol 2004; 2:289-300
21. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: The importance of early intervention and rapid attainment of the pharmacokinetic/ pharmacodynamic target. Antimicrob Agents Chemother 2012; 56:2795-805
22. Lodise TP, Butterfield J. Use of pharmacodynamic principles to inform beta-lactam dosing: "S" does not always mean success. J Hosp Med 2011; 6 (Suppl 1):S16-23
23. Lodise TP, Drusano GL. Pharmacokinetics and pharmacodynamics: Optimal antimicrobial therapy in the intensive care unit. Crit Care Clin 2011; 27:1-18
24. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010; 54:2063-9
25. Jones RN, Moet GJ, Sader HS, Mendes RE, Castanheira M. TR-700 in vitro activity against and resistance mutation frequencies among grampositive pathogens. J Antimicrob Chemother 2009; 63:716-20
26. Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009; 63: 713-5
27. Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against grampositive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:4608-13
28. Rodriguez-Avial I, Culebras E, Betriu C, Morales G, Pena I, Picazo JJ. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012; 67:167-9
29. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009; 53:3236-9
30. Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008; 52:4442-7
31. Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 55:5300-5
32. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother 2012; 56:2627-34
33. Lepak AJ, Marchillo K, Pichereau S, CraigWA, Andes DR. Comparative pharmacodynamics of a new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 2012; 56:5916-22
34. Louie A, Liu W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 55:3453-60
35. Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillinsensitive Streptococcus pneumoniae. Antimicrob Agents Chemother 2012; 56:4713-7
36. Keel RA, Crandon JL, Nicolau DP. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother 2012; 56:3420-2
37. Keel RA, Tessier PR, Crandon JL, Nicolau DP. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother 2012; 56:4403-7
38. Tessier PR, Keel RA, HagiharaM, Crandon JL, Nicolau DP. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother 2012; 56:2342-6
39. Andes D, Craig WA. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002; 46:1665-70
40. Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): Studies with human macrophage (THP-1) and endothelial (HUVEC)cell lines. J Antimicrob Chemother 2009; 64:1035-43
41. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, doubleblind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011; 55:583-92
42. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial. JAMA 2013; 309:559-69
43. De Anda C, Fang E, Green S, Mehra P, Das A, Prokocimer P. Comparison of investigator-assessed and programmatic clinical outcomes of tedizolid phosphate vs. linezolid in a phase 3 study in patients with ABSSSI [poster #L1-1665]. In Poster presentation at the 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 9-12 September, 2012; San Francisco, CA.
44. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52:24-36